$CCEL
CRYO CELL INTERNATIONAL INC

2020 Q4 Form 10-Q Financial Statement

#000156459020046540 Filed on October 15, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q4
Revenue $7.541M $8.114M $7.970M
YoY Change -5.39% -1.33% -7.26%
Cost Of Revenue $2.313M $2.360M $2.352M
YoY Change -1.65% -8.84% -12.06%
Gross Profit $5.227M $5.754M $5.618M
YoY Change -6.95% 2.13% -5.08%
Gross Profit Margin 69.32% 70.91% 70.49%
Selling, General & Admin $3.490M $3.376M $3.942M
YoY Change -11.46% -5.08% -4.32%
% of Gross Profit 66.76% 58.67% 70.16%
Research & Development $7.060K $1.248K $16.86K
YoY Change -58.13% -48.85% -37.37%
% of Gross Profit 0.14% 0.02% 0.3%
Depreciation & Amortization $87.60K $93.82K $96.85K
YoY Change -9.55% -2.43% -6.02%
% of Gross Profit 1.68% 1.63% 1.72%
Operating Expenses $1.763M $3.377M $4.005M
YoY Change -55.99% -5.11% -4.68%
Operating Profit $3.464M $2.480M $1.613M
YoY Change 114.81% 24.44% -6.07%
Interest Expense -$349.6K $338.7K -$351.6K
YoY Change -0.6% -18.18% -36.23%
% of Operating Profit -10.09% 13.66% -21.8%
Other Income/Expense, Net $20.00 $17.00 $30.14K
YoY Change -99.93% -100.0% -176.81%
Pretax Income $1.831M $936.0K $1.291M
YoY Change 41.77% -42.04% -16.24%
Income Tax $630.8K $151.6K $446.3K
% Of Pretax Income 34.46% 16.19% 34.56%
Net Earnings $1.200M $784.5K $845.0K
YoY Change 42.0% -29.72% -5.14%
Net Earnings / Revenue 15.91% 9.67% 10.6%
Basic Earnings Per Share $0.10
Diluted Earnings Per Share $147.2K $0.10 $101.1K
COMMON SHARES
Basic Shares Outstanding 7.546M 7.546M 7.803M
Diluted Shares Outstanding 8.179M

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.17M $8.170M $7.445M
YoY Change 50.01% -0.53% 7.65%
Cash & Equivalents $10.36M $8.108M $6.541M
Short-Term Investments $807.0K $62.72K $904.1K
Other Short-Term Assets $244.7K $287.0K $260.4K
YoY Change -6.03% 10.41% 2.33%
Inventory $927.3K $1.203M $1.085M
Prepaid Expenses $611.6K $599.4K $500.3K
Receivables $6.323M $6.504M $6.097M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $18.56M $16.76M $15.39M
YoY Change 20.59% 5.3% 4.25%
LONG-TERM ASSETS
Property, Plant & Equipment $1.641M $1.664M $1.846M
YoY Change -11.14% -5.95% 23.64%
Goodwill $1.941M $1.941M $1.941M
YoY Change 0.0% 0.0% 0.0%
Intangibles $1.182M $1.199M $1.249M
YoY Change -5.42% -5.51% -6.86%
Long-Term Investments $308.0K $308.0K $308.0K
YoY Change 0.0% 0.0% 0.0%
Other Assets $26.00M $26.01M $25.65M
YoY Change 1.37% 7.76% -1.85%
Total Long-Term Assets $27.64M $27.68M $27.50M
YoY Change 0.53% 6.83% -2.23%
TOTAL ASSETS
Total Short-Term Assets $18.56M $16.76M $15.39M
Total Long-Term Assets $27.64M $27.68M $27.50M
Total Assets $46.20M $44.44M $42.89M
YoY Change 7.73% 6.25% 0.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $957.4K $900.0K $1.369M
YoY Change -30.07% -11.16% 8.52%
Accrued Expenses $2.898M $1.049M $2.085M
YoY Change 38.99% -23.59% -22.85%
Deferred Revenue $9.183M $9.107M $8.875M
YoY Change 3.47% 3.71% 6.09%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.100M $3.100M $3.100M
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $16.41M $14.43M $15.43M
YoY Change 6.39% 1.13% 0.0%
LONG-TERM LIABILITIES
Long-Term Debt $2.841M $3.598M $5.856M
YoY Change -51.48% -45.52% 310.96%
Other Long-Term Liabilities $32.45M $34.05M $34.41M
YoY Change -5.69% -1.38% -4.07%
Total Long-Term Liabilities $32.45M $34.05M $34.41M
YoY Change -5.69% -1.38% -7.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.41M $14.43M $15.43M
Total Long-Term Liabilities $32.45M $34.05M $34.41M
Total Liabilities $48.87M $48.48M $49.84M
YoY Change -1.95% -0.64% -2.84%
SHAREHOLDERS EQUITY
Retained Earnings -$18.82M -$20.02M -$22.44M
YoY Change -16.15% -14.04% -11.39%
Common Stock $36.72M $36.55M $36.05M
YoY Change 1.84% 1.81% 1.13%
Preferred Stock
YoY Change
Treasury Stock (at cost) $20.56M $20.56M $20.56M
YoY Change 0.0% 5.07% 5.07%
Treasury Stock Shares $6.094M $6.094M $6.094M
Shareholders Equity -$2.665M -$4.036M -$6.953M
YoY Change
Total Liabilities & Shareholders Equity $46.20M $44.44M $42.89M
YoY Change 7.73% 6.25% 1.17%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q4
OPERATING ACTIVITIES
Net Income $1.200M $784.5K $845.0K
YoY Change 42.0% -29.72% -5.14%
Depreciation, Depletion And Amortization $87.60K $93.82K $96.85K
YoY Change -9.55% -2.43% -6.02%
Cash From Operating Activities $2.977M $2.052M $1.199M
YoY Change 148.3% -25.18% 42.04%
INVESTING ACTIVITIES
Capital Expenditures -$47.56K -$2.170K -$155.0K
YoY Change -69.31% -97.8% 309.3%
Acquisitions
YoY Change
Other Investing Activities $99.36K $358.1K -$29.36K
YoY Change -438.42% 35709.0% -5.47%
Cash From Investing Activities $51.80K $355.9K -$184.3K
YoY Change -128.1% -465.16% 167.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -775.0K -2.720M -1.812M
YoY Change -57.24% 53.24% 2.1%
NET CHANGE
Cash From Operating Activities 2.977M 2.052M 1.199M
Cash From Investing Activities 51.80K 355.9K -184.3K
Cash From Financing Activities -775.0K -2.720M -1.812M
Net Change In Cash 2.254M -312.0K -797.7K
YoY Change -382.49% -135.85% -20.22%
FREE CASH FLOW
Cash From Operating Activities $2.977M $2.052M $1.199M
Capital Expenditures -$47.56K -$2.170K -$155.0K
Free Cash Flow $3.024M $2.054M $1.354M
YoY Change 123.4% -27.69% 53.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7545613
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1846467
CY2019Q4 us-gaap Inventory Net
InventoryNet
1084533
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1198504
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
260397
CY2020Q3 us-gaap Assets Current
AssetsCurrent
16763663
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8107608
CY2019Q4 us-gaap Assets Current
AssetsCurrent
15387611
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34677
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1663892
dei City Area Code
CityAreaCode
813
dei Document Transition Report
DocumentTransitionReport
false
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6541037
dei Local Phone Number
LocalPhoneNumber
749-2100
dei Entity Address City Or Town
EntityAddressCityOrTown
Oldsmar
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2020Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
62716
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
904053
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6503550
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6097331
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
599429
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
500260
CY2020Q3 us-gaap Inventory Net
InventoryNet
1203328
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
287032
dei Security Exchange Name
SecurityExchangeName
NONE
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1249254
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
12646000
CY2019Q4 us-gaap Goodwill
Goodwill
1941411
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
9079994
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
23846357
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1615007
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
151570
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
498748
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
784467
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
1116259
us-gaap Net Income Loss
NetIncomeLoss
2424771
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7545613
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7803333
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8179465
us-gaap Profit Loss
ProfitLoss
2424771
us-gaap Profit Loss
ProfitLoss
1445809
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
284689
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
304463
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1032
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-636278
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10949831
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-169741
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16791
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13281
us-gaap Depreciation And Amortization
DepreciationAndAmortization
130034
us-gaap Depreciation And Amortization
DepreciationAndAmortization
159600
us-gaap Costs And Expenses
CostsAndExpenses
18125499
us-gaap Costs And Expenses
CostsAndExpenses
20503050
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2100167
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
783960
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
654358
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3208731
CY2020Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
12289477
CY2020Q3 us-gaap Goodwill
Goodwill
1941411
CY2020Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
9079994
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
365696
CY2020Q3 ccel Deposits And Other Assets
DepositsAndOtherAssets
479526
CY2019Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
427423
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
26012608
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
25652082
CY2020Q3 us-gaap Assets
Assets
44440163
CY2019Q4 us-gaap Assets
Assets
42886160
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
899951
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1369111
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1048762
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2085180
CY2020Q3 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
271932
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9107027
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8875138
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14427672
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15429429
CY2020Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
26201441
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
23633373
CY2020Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
3280316
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
3495057
CY2020Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
3598164
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5856152
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
93904
CY2020Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2019Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
1425000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34048825
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34409582
CY2020Q3 us-gaap Liabilities
Liabilities
48476497
CY2019Q4 us-gaap Liabilities
Liabilities
49839011
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
136336
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
135989
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36410226
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35918827
CY2020Q3 us-gaap Treasury Stock Value
TreasuryStockValue
20563357
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
20563357
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20019539
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22444310
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-4036334
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-6952851
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44440163
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42886160
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2772550
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2584091
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7544124
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7802676
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
us-gaap Net Income Loss
NetIncomeLoss
1445809
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8137463
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8430251
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.19
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13633638
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13598909
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7545613
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7510884
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8114358
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8223393
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
23606976
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2360324
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2589335
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7344011
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7683853
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3375807
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3556602
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10804404
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
CY2020Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-145752
CY2019Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
34649
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1248
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2440
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
42510
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
47286
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
5634137
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
6230312
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2480221
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1993081
CY2020Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-134626
CY2019Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
34882
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
986
CY2020Q3 us-gaap Interest Expense
InterestExpense
338675
CY2019Q3 us-gaap Interest Expense
InterestExpense
413942
CY2020Q3 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-1070900
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-1070900
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8445237
us-gaap Share Based Compensation
ShareBasedCompensation
450746
us-gaap Share Based Compensation
ShareBasedCompensation
239983
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
501312
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
587716
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
67010
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
239983
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3364297
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1566571
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1298756
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
86014
ccel Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
197079
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
907531
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
608537
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
99169
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
64473
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-237728
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-25265
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
26635
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
5506
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
52103
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-30832
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-469160
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-248616
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-757318
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1311841
ccel Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-196939
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2799957
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2991800
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5489878
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5170392
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
52396
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
507339
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
350000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
708087
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
305691
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-507339
ccel Payments For Extinguishment Of Revenue Sharing Agreements
PaymentsForExtinguishmentOfRevenueSharingAgreements
1900000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2324998
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3324997
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
41000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5700
ccel Payment Of Earnout
PaymentOfEarnout
45000
ccel Payment Of Earnout
PaymentOfEarnout
45000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4228998
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6040033
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7338789
ccel Operating Leaseright Of Useasset Recorded Due To Adoption Of Asc842
OperatingLeaserightOfUseassetRecordedDueToAdoptionOfAsc842
562775
ccel Operating Lease Liability Recorded Due To Adoption Of Asc842
OperatingLeaseLiabilityRecordedDueToAdoptionOfAsc842
562775
ccel Cumulative Effect Adjustment Due To Adoption Of Accounting Standard Update
CumulativeEffectAdjustmentDueToAdoptionOfAccountingStandardUpdate
-340984
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-4982795
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
161994
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
41000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
450746
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-8093792
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
14174
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-6963359
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-8908298
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5700
ccel Cumulative Effect On Retained Earnings Tax
CumulativeEffectOnRetainedEarningsTax
94192
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5867335
ccel Covid19
Covid19
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Palatino Linotype;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Note 13 &#8211; COVID-19</font></p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Palatino Linotype;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (&#8220;COVID-19&#8221;) outbreak.&#160; The Company faces various risks related to health epidemics, pandemics and similar outbreaks, including the global outbreak of COVID-19.&nbsp;&nbsp;The Company believes it has taken appropriate steps to minimize the risk to our employees and to maintain normal business operations but cannot at this time predict the impact of the COVID-19 pandemic.&nbsp;&nbsp;It could have a material adverse effect on the business, financial position, results of operations and/or cash flows.&nbsp;&nbsp;Operating results for the nine months ended August 31, 2020, are not necessarily indicative of the results that may be expected for the fiscal year ending November 30, 2020.&nbsp;&nbsp;</p>
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
35308468
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Palatino Linotype;font-style:normal;text-transform:none;font-variant: normal;">Product Warranty and Cryo-Cell Cares<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> Program</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Palatino Linotype;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions.&nbsp;&nbsp;Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients.&nbsp;&nbsp;Effective June 1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, PrepaCyte CB.&nbsp;&nbsp;Additionally, under the Cryo-Cell Cares<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloablative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company.&nbsp;&nbsp;The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties.&nbsp;&nbsp;</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Palatino Linotype;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer.&nbsp;&nbsp;Upon the adoption of ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method, therefore, the transaction price does not reflect any expectation of service level credits at August 31, 2020.&nbsp;&nbsp; At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</p>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2020Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
35308468
CY2020Q3 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
9107027
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2017Q2 ccel Reimbursement Of Personal Expenses
ReimbursementOfPersonalExpenses
10000
CY2020Q3 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
14261
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
37405
CY2019Q3 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
10747
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
25216
CY2018Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
329231
CY2018Q4 us-gaap Capitalized Contract Cost Accumulated Amortization
CapitalizedContractCostAccumulatedAmortization
66533
CY2020Q3 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
22351
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
68152
CY2019Q3 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
23180
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
67668
CY2020Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
450638
CY2019Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
329231
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5867335
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8365284
CY2019Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
20317231
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
398535
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
68152
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
16049
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
28361238
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
27955019
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
32508511
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
13045728
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
10245771
CY2018Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
329231
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
67668
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
13500
CY2019Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
383399
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
27615196
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
27594375
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5888156
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
28682515
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
14184601
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
11192801
CY2019Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
31674315
CY2019Q3 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
CY2020Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2019Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2020Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2019Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2020Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q3 ccel Number Of Employee Stock Based Compensation Plan
NumberOfEmployeeStockBasedCompensationPlan
2
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
451000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
240000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
162000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14000
CY2019Q1 ccel Cumulative Effect Adjustment From Accumulated Other Comprehensive Income To Retained Earnings
CumulativeEffectAdjustmentFromAccumulatedOtherComprehensiveIncomeToRetainedEarnings
341000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-133000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-1000
CY2020Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-135000
CY2019Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
35000
ccel Loss On Cash Liquidating Distribution
LossOnCashLiquidatingDistribution
175000
CY2020Q3 ccel Loss On Cash Liquidating Distribution
LossOnCashLiquidatingDistribution
175000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
CY2012Q1 ccel Additional Payment Warranty
AdditionalPaymentWarranty
10000
CY2019Q2 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
CY2020Q3 ccel Inventory Collection Kits
InventoryCollectionKits
35622
CY2019Q4 ccel Inventory Collection Kits
InventoryCollectionKits
44453
CY2020Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2020Q3 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
13492805
CY2019Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
13730533
CY2020Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1198504
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1249254
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17000
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
19000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
51000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
73000
CY2020Q3 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
548085
CY2020Q3 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
20193
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
67012
CY2019Q3 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
28014
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
86014
CY2020Q3 us-gaap Notes Payable
NotesPayable
6783433
CY2019Q4 us-gaap Notes Payable
NotesPayable
9108433
CY2020Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
85269
CY2019Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
152281
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
6698164
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
8956152
CY2020Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
63560
us-gaap Interest Expense Debt
InterestExpenseDebt
254945
CY2020Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.52
CY2020Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1047166
CY2020Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
3.23
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
125234
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
51969
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
102626
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
74577
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.70
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.62
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.98
CY2020Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
83753
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
321957
CY2019Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
162134
us-gaap Interest Expense Debt
InterestExpenseDebt
523818
CY2019Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
190148
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
609832
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
633852
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
641904
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
593339
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
627575
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
110965
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
112465
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.94
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.32
CY2020Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1121743
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P3Y5M19D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2020 and the remaining 1/3 on November 30, 2021.
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
14000
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2020Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
6093535
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
6093535
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
365836
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
71212
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
284846
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
23737
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
13959
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.053
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
65754
us-gaap Operating Lease Payments
OperatingLeasePayments
196940
CY2020Q2 us-gaap Line Of Credit
LineOfCredit
350000
CY2020Q2 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
150000

Files In Submission

Name View Source Status
0001564590-20-046540-index-headers.html Edgar Link pending
0001564590-20-046540-index.html Edgar Link pending
0001564590-20-046540.txt Edgar Link pending
0001564590-20-046540-xbrl.zip Edgar Link pending
ccel-10q_20200831.htm Edgar Link pending
ccel-20200831.xml Edgar Link completed
ccel-20200831.xsd Edgar Link pending
ccel-20200831_cal.xml Edgar Link unprocessable
ccel-20200831_def.xml Edgar Link unprocessable
ccel-20200831_lab.xml Edgar Link unprocessable
ccel-20200831_pre.xml Edgar Link unprocessable
ccel-ex311_10.htm Edgar Link pending
ccel-ex312_8.htm Edgar Link pending
ccel-ex313_6.htm Edgar Link pending
ccel-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending